PGT-A Evaluates Advanced Sperm Selection in Embryos From High Teratozoospermia Males

Launched by GANIN FERTILITY CENTER · Jan 29, 2024

Keywords

ClinConnect Summary

Couples seeking infertility treatment are becoming more frequent. Paternal factor shows one of the infertility causes which may have a negative impact on reproductive outcomes. Intracytoplasmic sperm injection (ICSI) is thought to be the most effective way to treat infertility. Sperm morphology evaluation is a reliable predictor of male fertility while teratozoospermia index (TZI) is a unique expression of sperm morphological assessment. A higher rate of abnormal sperm morphology tends to have higher sperm chromosomal abnormality rates. The choice of high-quality sperm through sperm selecti...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males diagnosed with normal and high teratozoospermia index.
• • 2. Males with Mild to moderate OTA (oligoteratoasthenozoospermia).
• • 3. Males aged 18-60 years.
• • 4. Female aged 18-40 years.
• • 5. Case must have PGT-A for all of her blastocysts.
• • 6. Normo responder (\> 5 mature oocytes).
• • 7. Male will have to refrain from ejaculation no less than 1 day but no greater than 3 days prior semen specimen production on day of ICSI.
• Exclusion Criteria:
• • 1. Leukocytospermia.
• • 2. Presence of varicocele.
• • 3. Known genetic abnormality.
• • 4. Use of sperm or oocyte donors.
• • 5. Use of gestational carrier.
• • 6. Presence of any of the endometrial factors that affect embryo implantation such as hydrosalpings, adenomyosis or previous uterine infection.
• • 7. Any contradictions to undergoing in vitro fertilization or gonadotropin stimulation.

Trial Officials